The Potential of Probiotics to Prevent Clostridium difficile Infection

Infectious Disease Clinics of North America

Volumn 29, Issue 1, 2015, Pages 135-144

  Allen, Stephen J ^a  

^a LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Bifidobacteria; C difficile diarrhea; Lactobacilli; Probiotic; Saccharomyces boulardii

Indexed keywords

ANTIBIOTIC AGENT; PLACEBO; PROBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC ASSOCIATED DIARRHEA; BACTERIAL COLONIZATION; BIFIDOBACTERIUM; CLOSTRIDIUM DIFFICILE INFECTION; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS CASEI; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; REVIEW; SACCHAROMYCES BOULARDII; STREPTOCOCCUS THERMOPHILUS; CLINICAL TRIAL (TOPIC); CLOSTRIDIUM INFECTIONS; COMPLICATION; DIARRHEA; INTESTINAL DISEASES; MICROBIOLOGY; PHYSIOLOGY; RISK FACTOR; SACCHAROMYCES;

ANTI-BACTERIAL AGENTS; BIFIDOBACTERIUM; CLINICAL TRIALS AS TOPIC; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; HUMANS; INTESTINAL DISEASES; LACTOBACILLUS; PROBIOTICS; RISK FACTORS; SACCHAROMYCES;

EID: 84922817126     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2014.11.002     Document Type: Review

References (42)

1. Viswanathan V.K., Mallozzi M.J., Vedantam G. Clostridium difficile infection: an overview of the disease and its pathogenesis, epidemiology and interventions. Gut Microbes 2010, 1:234-242.
2. Dubberke E.R., Haslam D.B., Lanzas C., et al. The ecology and pathobiology of Clostridium difficile infections: an interdisciplinary challenge. Zoonoses Public Health 2011, 58:4-20.
3. Loo V.G., Bourgault A.M., Poirier L., et al. Host and pathogen factors for Clostridium difficile infection and colonization. NEngl J Med 2011, 365:1693-1703.
4. Bauer M.P., Notermans D.W., van Benthem B.H., et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011, 377:63-73.
5. Allen S.J., Wareham K., Wang D., et al. Ahigh-dose preparation of lactobacilli and Bifidobacteria in the prevention of antibiotic-associated and Clostridium difficile diarrhoea in older people admitted to hospital: a multicentre, randomised, double-blind, placebo-controlled, parallel arm trial (PLACIDE). Health Technol Assess 2013, 17:1-140.
6. Food and Agriculture Organization of the UN and WHO Report of a joint FAO/WHO working group on drafting guidelines for the evaluation of probiotics in food 2002, World Health Organization, Geneva (Switzerland), Available at:, Accessed July 8, 2014. http://www.who.int/entity/foodsafety/fs_management/en/probiotic_guidelines.pdf.
7. Parkes G.C., Sanderson J.D., Whelan K. The mechanisms and efficacy of probiotics in the prevention of Clostridium difficile-associated diarrhoea. Lancet Infect Dis 2009, 9:237-244.
8. Goldenberg J.Z., Ma S.S., Saxton J.D., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2013, (5). CD006095.
9. Hempel S., Newberry S., Ruelaz A., et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep) 2011, 200:1-645.
10. Whelan K., Myers C.E. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. Am J Clin Nutr 2010, 91:687-703.
11. Hammerman C., Bin-Nun A., Kaplan M. Safety of probiotics: comparison of two popular strains. BMJ 2006, 333:1006-1008.
12. Antunes L.C., Han J., Ferreira R.B., et al. Effect of antibiotic treatment on the intestinal metabolome. Antimicrob Agents Chemother 2011, 55:1494-1503.
13. Pothoulakis C., Lamont J.T. Microbes and microbial toxins: paradigms for microbial-mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 2001, 280:G178-G183.
14. Britton R.A., Young V.B. Role of the intestinal microbiota in resistance to colonization by Clostridium difficile. Gastroenterology 2014, 146:1547-1553.
15. Plummer S., Weaver M.A., Harris J.C., et al. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 2004, 7:59-62.
16. Ohland C.L., Macnaughton W.K. Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 2010, 298:G807-G819.
17. Hell M., Bernhofer C., Stalzer P., et al. Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic. Benef Microbes 2013, 4:39-51.
18. Naaber P., Smidt I., Stsepetova J., et al. Inhibition of Clostridium difficile strains by intestinal Lactobacillus species. JMed Microbiol 2004, 53:551-554.
19. Tejero-Sariñena S., Barlow J., Costabile A., et al. Antipathogenic activity of probiotics against Salmonella Typhimurium and Clostridium difficile in anaerobic batch culture systems: is it due to synergies in probiotic mixtures or the specificity of single strains?. Anaerobe 2013, 24:60-65.
20. Schoster A., Kokotovic B., Permin A., et al. Invitro inhibition of Clostridium difficile and Clostridium perfringens by commercial probiotic strains. Anaerobe 2013, 20:36-41.
21. Boonma P., Spinler J.K., Venable S.F., et al. Lactobacillus rhamnosus L34 and Lactobacillus casei L39 suppress Clostridium difficile-induced IL-8 production by colonic epithelial cells. BMC Microbiol 2014, 14:177.
22. Chapman C.M., Gibson G.R., Rowland I. Health benefits of probiotics: are mixtures more effective than single strains?. Eur J Nutr 2011, 50:1-17.
23. Timmerman H.M., Koning C.J., Mulder L., et al. Monostrain, multistrain and multispecies probiotics - a comparison of functionality and efficacy. Int J Food Microbiol 2004, 96:219-233.
24. Schubert A.M., Rogers M.A., Ring C., et al. Microbiome data distinguish patients with Clostridium difficile infection and non-C. difficile-associated diarrhea from healthy controls. MBio 2014, 5. e01021-14.
25. Skraban J., Dzeroski S., Zenko B., et al. Gut microbiota patterns associated with colonization of different Clostridium difficile ribotypes. PLoS One 2013, 8:e58005.
26. Arumugam M., Raes J., Pelletier E., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
27. Claesson M.J., Cusack S., O' Sullivan O., et al. Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 2011, 108(Suppl 1):4586-4591.
28. Stevens V., Dumyati G., Fine L.S., et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis 2011, 53:42-48.
29. Hempel S., Newberry S.J., Maher A.R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA 2012, 307:1959-1969.
30. Dendukuri N., Costa V., McGregor M., et al. Probiotic therapy for the prevention and treatment of Clostridium difficile -associated diarrhea: a systematic review. CMAJ 2005, 173:167-170.
31. Johnston B.C., Ma S.S., Goldenberg J.Z., et al. Probiotics for the Prevention of Clostridium difficile- associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012, 18:878-888.
32. Hickson M. Probiotics in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection. Therap Adv Gastroenterol 2011, 4:185-197.
33. Gao X.W., Mubasher M., Fang C.Y., et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol 2010, 105:1636-1641.
34. Allen S.J., Wareham K., Wang D., et al. Lactobacilli and Bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2013, 382:1249-1257.
35. Hickson M., D'Souza A.L., Muthu N., et al. Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 2007, 335:80.
36. McFarland L.V. Diarrhoea associated with antibiotic use. BMJ 2007, 335:54-55.
37. McFarland L.V. Deciphering meta-analytic results: a mini-review of probiotics for the prevention of paediatric antibiotic-associated diarrhoea and Clostridium difficile infections. Benef Microbes 2014, 1-6. Accessed July 9, 2014. 10.3920/BM2014.0034.
38. Ziakas P.D., Mylonakis E. Probiotics did not prevent antibiotic-associated or C.difficile diarrhea in hospitalized older patients. Ann Intern Med 2014, 160:JC6.
39. Health Protection Agency. Results from the mandatory Clostridium difficile reporting scheme. 2013. Available at: . Accessed July 10, 2014. http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/ClostridiumDifficile/EpidemiologicalData/MandatorySurveillance/cdiff%20MandatoryReportingScheme/.
40. Public Health Wales. All Wales Commentaries: Clostridium difficile reports. 2012. Available at: . Accessed July 10, 2014. http://www.wales.nhs.uk/sites3/page.cfm?orgid=379%26pid=18490.
41. Kanerva M., Mentula S., Virolainen-Julkunen A., et al. Reduction in Clostridium difficile infections in Finland, 2008-2010. JHosp Infect 2013, 83:127-131.
42. Janarthanan S., Ditah I., Adler D.G., et al. Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012, 107:1001-1010.